HBV Reactivation Risk With DAA Therapies vs. Interferon for HCV HBV Reactivation Risk With DAA Therapies vs. Interferon for HCV

Do direct-acting antiviral-based therapies for HCV have more potential to cause frequent HBV reactivation compared with interferon-based therapies?Journal of Viral Hepatitis
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news